基于Treg细胞的免疫疗法在自身免疫性肝炎中的研究进展
Research progress of Treg cell-based immunotherapy in autoimmune hepatitis
黄卓 1黄会芳 2姚佳心 1付泽花1
作者信息
- 1. 山西医科大学第一临床医学院,山西 太原 030001
- 2. 山西医科大学第一医院消化内科
- 折叠
摘要
自身免疫性肝炎(autoimmune hepatitis,AIH)是一种慢性炎症性疾病,患者需长期依赖于激素和/或免疫抑制剂治疗,且停药后疾病易复发.因此,需针对其发病机制开发更有效的治疗手段.目前的研究指出,AIH 的发病主要源于自身免疫耐受的异常,而其原因主要归结于 Treg细胞数量及功能的下降.近年来研究者针对 Treg细胞在 AIH发病中的作用及可能的治疗靶点进行了多项深入研究,如过继转移 Treg细胞、抗原特异性 Treg细胞的开发、免疫微环境对 Treg 细胞的影响、Foxp3 去甲基化表达、针对 Treg细胞的 CD39-CD73-腺苷通路药物靶点研究等,本文综述以上研究,以期为开发 AIH更有效的治疗手段提供科学依据.
Abstract
Autoimmune hepatitis(AIH)is a chronic inflammatory disease that is dependent on hormonal and/or im-munosuppressive therapy for a long period of time and prone to relapse after discontinuation.Therefore,it is necessary to develop more effective treatments for its pathogenesis.Current studies indicate that the pathogenesis of AIH is mainly due to abnormal autoimmune tolerance,which is mainly attributed to the decline in the number and function of Treg cells.In recent years,researchers have conducted many in-depth studies on the role of Treg cells in AIH pathogenesis and possible therapeutic targets.These studies include adoptive transfer Treg cells,development of antigen-specific Treg cells,effects of immune microenvironment on Treg cells,Foxp3 demethylation expression,and drug targets of CD39-CD73-adenosine pathway targeting Treg cells.This review aimed to provide scientific basis for the development of more effective treatments for AIH.
关键词
自身免疫性肝炎/调节性T细胞/免疫疗法Key words
Autoimmune hepatitis/Regulatory T cells/Immunotherapy引用本文复制引用
基金项目
山西省自然科学基金(201901D111357)
出版年
2024
NETL
NSTL
万方数据